Patents by Inventor John L. Diener

John L. Diener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Organic Compositions to Treat Beta-ENaC-Related Diseases
    Publication number: 20110263681
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: April 20, 2011
    Publication date: October 27, 2011
    Applicant: NOVARTIS AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
  • Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
    Patent number: 8039443
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: October 18, 2011
    Assignee: Archemix Corporation
    Inventors: Dilara Grate, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Aptamers that bind thrombin with high affinity
    Patent number: 7998939
    Abstract: The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: August 16, 2011
    Assignee: Archemix Corporation
    Inventors: John L. Diener, Jess Wagner-Whyte, David Fontana
  • Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics
    Patent number: 7998940
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: August 16, 2011
    Assignee: Archemix Corp.
    Inventors: John L. Diener, H. A. Daniel Lagasse, Claude Benedict
  • Regulated aptamer therapeutics
    Patent number: 7960102
    Abstract: Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: June 14, 2011
    Assignee: Archemix Corp.
    Inventors: David Epstein, Charles Wilson, John L. Diener
  • Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics
    Publication number: 20110098345
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Application
    Filed: August 17, 2010
    Publication date: April 28, 2011
    Inventors: Robert G. Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey C. Kurz, John L. Diener
  • Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
    Patent number: 7767803
    Abstract: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2?-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: August 3, 2010
    Assignee: Archemix Corp.
    Inventors: John L. Diener, Paul Hatala, Jess Wagner-Whyte, Charles Wilson
  • Materials and methods for the generation of transcripts comprising modified nucleotides
    Publication number: 20100120024
    Abstract: Materials and Methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 13, 2010
    Inventors: Sharon Cload, John L. Diener, Anthony Dominic Keefe, Kristin Thompson
  • Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
    Patent number: 7589073
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: September 15, 2009
    Assignee: Archemix Corp.
    Inventors: John L. Diener, H. A. Daniel Lagassé, Claude Benedict
  • Aptamers that bind thrombin with high affinity
    Publication number: 20090221680
    Abstract: The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin.
    Type: Application
    Filed: August 23, 2006
    Publication date: September 3, 2009
    Inventors: John L. Diener, Jess Wagner-Whyte, David Fontana
  • Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
    Patent number: 7579450
    Abstract: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: August 25, 2009
    Assignee: Archemix Corp.
    Inventors: Paula Burmeister, Sharon Cload, John L. Diener, Anthony Dominic Keefe, Sara Chesworth Keene, Markus Kurz, H. A. Daniel Lagassé, Harold Nicholas Marsh, Pooja Sawhney, Chunhua Wang
  • Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
    Patent number: 7566701
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: July 28, 2009
    Assignee: Archemix Corp.
    Inventors: John L. Diener, H. A. Daniel Lagassé, Claude Benedict
  • Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics
    Publication number: 20090149643
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor.
    Type: Application
    Filed: January 29, 2009
    Publication date: June 11, 2009
    Applicant: Archemix Corp.
    Inventors: John L. Diener, H.A. Daniel Lagasse, Claude Benedict
  • Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
    Publication number: 20090105172
    Abstract: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2?-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.
    Type: Application
    Filed: March 7, 2006
    Publication date: April 23, 2009
    Inventors: John L. Diener, Paul Hatala, Jason R. Killough, Jess Wagner-Whyte, Charles Wilson, Shuhao Zhu
  • Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
    Publication number: 20090082555
    Abstract: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
    Type: Application
    Filed: June 9, 2008
    Publication date: March 26, 2009
    Inventors: John L. Diener, Alicia Ferguson, Nobuko Hamaguchi, Sara Chesworth Keene, H.A. Daniel Lagasse, Pooja Sawhney, Kristin Thompson
  • Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics
    Publication number: 20090018093
    Abstract: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.
    Type: Application
    Filed: December 1, 2005
    Publication date: January 15, 2009
    Inventors: Sharon Cload, John L. Diener, David Epstein, Jess Wagner-Whyte
  • Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
    Publication number: 20040253679
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: April 21, 2004
    Publication date: December 16, 2004
    Inventors: David Epstein, Dilara Grate, Martin Stanton, John L. Diener, Charles Wilson, Thomas McCauley, Errol DeSouza
  • Prophylactic and therapeutic HIV aptamers
    Publication number: 20040137010
    Abstract: Materials and methods of use thereof are presented for the prophylactic treatment of HIV. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of HIV disease are presented with methods of administering these therapeutic compositions as vaccines against HIV infection.
    Type: Application
    Filed: September 16, 2003
    Publication date: July 15, 2004
    Inventors: Charles Wilson, David Epstein, John L. Diener
  • Therapeutic aptamers having binding specificity to gp41 of HIV
    Publication number: 20040137429
    Abstract: Materials and methods of use thereof are presented for the treatment or diagnosis of HIV. The materials are aptamers that bind to gp41, CCR5 or other HIV viral targets that are involved in the formation of the gp41 fusion-active intermediate.
    Type: Application
    Filed: October 1, 2003
    Publication date: July 15, 2004
    Inventors: David Epstein, Jill Blanchard, Charles Wilson, John L. Diener
  • Regulated aptamer therapeutics
    Publication number: 20040110235
    Abstract: Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.
    Type: Application
    Filed: July 25, 2003
    Publication date: June 10, 2004
    Inventors: David Epstein, Charles Wilson, John L. Diener